Chemkart India is evolving from a B2B nutraceutical distributor to a  high-margin CDMO player, backed by strong industry tailwinds and strategic execution.

  • Positioned to benefit from India’s  $76B nutraceutical opportunity
  • Building a  greenfield SEZ manufacturing facility  with advanced technologies
  • Strong financial track record:  32% revenue CAGR | 64% PAT CAGR
  • Targeting  ₹450 Cr revenue by FY28
  • Valuation upside of ~170% with a BUY call

The growth story is driven by  backward integration, global expansion, and innovation-led manufacturing.

Detailed Analysis in the coverage report

Link to download the Report